Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cretostimogene grenadenorepvec + nivolumab
- Development stage
- Unknown
- Lead developer
- CG Oncology
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravesical, Intravenous
01
Overview
Cretostimogene grenadenorepvec + nivolumab is an investigational combination therapy being evaluated for the treatment of bladder cancer. Cretostimogene grenadenorepvec (formerly CG0070) is a conditionally replicating oncolytic adenovirus (type 5) engineered to replicate specifically within tumor cells that have a dysfunctional retinoblastoma (Rb) pathway. The virus also carries a human GM-CSF transgene, which is released upon tumor cell lysis to stimulate a systemic immune response. Nivolumab is a fully human IgG4 monoclonal antibody that binds to the programmed death-1 (PD-1) receptor, blocking its interaction with PD-L1 and PD-L2, thereby reversing T-cell suppression. The H. Lee Moffitt Cancer Center and Research Institute is conducting a Phase 1 trial (NCT04612517) evaluating this combination as a neoadjuvant therapy for cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC).
- Brand names
- Opdivocretostimogene grenadenorepvec
- Other names
- CG0070 + nivolumab
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on cretostimogene grenadenorepvec + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cretostimogene grenadenorepvec + nivolumab.